

Research Leadership Award Presentation

Remo Panaccione

PROFESSOR OF MEDICINE
Crohn's COLITIS CANADA ENDOWED RESEARCH CHAIR
DIRECTOR, IBD UNIT
ASSISTANT DEAN of MD ADMISSIONS
UNIVERSITY OF CALGARY

INFLAMMATORY
BOWEL DISEASE UNIT
UNIVERSITY OF CALGARY

Disclosures

Remo Panaccione, MD, FRCPC

Consultant for: Abbott, AbbVie, Abbivax, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, UCB

Speaker's Fees for: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals

Advisory Boards for: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Sublimity Therapeutics, Takeda Pharmaceuticals, Ventyx.

In the beginning…the journey did not start off well

The importance of mentorship

The journey of your success will always begin with the small step of taking a chance.



Research Leadership Award: Journey

It was simple…

Gastroenterologist with an experience of… IBD

Expert in:

- Diagnosis / assessment and medical management of IBD
- Performance of clinical trials

Not expert in:

- Histopathology / radiology / surgery / fertility / obstetrics / dermatology / infectious diseases / rheumatology / nutrition / psychiatry / psychotherapy

Lacking expertise:

- Patient education
- Basic and translational research
- Other forms of clinical research

Therefore, my research career was built on a solid clinical foundation and focused on clinical strengths identified weaknesses


You never fail until
you stop trying.
Albert Einstein
quotefancy

University of Calgary: IBD unit evolution

1999
Arrive in Calgary

2001
Establish the IBD Clinic within Faculty of Medicine

2001
Enhance clinical trial capability

2001
Establish National presence via clinical guidelines

2003
Establish Translational Science Research Co-ordinator and Biobank

2004
Establish Global presence via clinical trials

2005
Establish physician preceptor-ships

2005
Time for growth: Identify the brightest and the best

$ $ $

In the beginning…

Review > Can J Gastroenterol. 2001 Jun;15(6):371-5. doi: 10.1155/2001/490921.

Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada

R Panaccione [1]; Canadian Consensus Group on the use of infliximab in Crohn's disease

Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease

Remo Panaccione [1], Richard N Fedorak, Guy Aumais, Charles N Bernstein, Alain Bitton, Ken Croitoru, Robert Enns, Brian Feagan, Marty Fishman, Gordon Greenberg, Anne Griffiths, John K Marshall, Imran Rasul, Daniel Sadowski, Ernest Seidman, Hillary Steinhart, Lloyd Sutherland, Eric Walli, Gary Wild, C Noel Williams, Mary Zachos; Canadian Association of Gastroenterology

In the beginning…

Review > Can J Gastroenterol. 2008 Mar;22(3):261-72. doi: 10.1155/2008/493405.

Review and clinical perspectives for the use of infliximab in ulcerative colitis

R Panaccione [1], R N Fedorak, G Aumais, Edmond-Jean Bernard, C N Bernstein, A Bitton, K Croitoru, L A Dieleman, R Enns, B G Feagan, D Franchimont, G R Greenberg, Anne-Marie Griffiths, J K Marshall, P Pare, S Patel, R Penner, C Render, E Seidman, A Hillary Steinhart

In the beginning…

Review > Aliment Pharmacol Ther. 2008 Sep 15;28(6):674-88.
doi: 10.1111/j.1365-2036.2008.03753.x.

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

R Panaccione [1], P Rutgeerts, W J Sandborn, B Feagan, S Schreiber, S Ghosh

Mentorship from outside

Randomized Controlled Trial > Gastroenterology. 2014 Feb;146(2):392-400.e3.
doi: 10.1053/j.gastro.2013.10.052.

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

Remo Panaccione, Subrata Ghosh, Stephen Middleton, Juan R Márquez, Boyd B Scott, Laurence Flint, Hubert J F van Hoogstraten, Annie C Chen, Hanzhe Zheng, Silvio Danese, Paul Rutgeerts



Clinical Trial > Inflamm Bowel Dis. 2015 Jun;21(6):1329-40.
doi: 10.1097/MIB.0000000000000366.

Briakinumab for treatment of Crohn's disease: results of a randomized trial

Remo Panaccione [1], William J Sandborn, Glenn L Gordon, Scott D Lee, Alan Safdi, Shahriar Sedghi, Brian G Feagan, Stephen Hanauer, Walter Reinisch, John F Valentine, Bidan Huang, Roberto Carcereri



FIGURE 3. Efficacy of briakinumab during the induction phase. A, Rates of clinical remission at weeks 6 and 12. Clinical remission was defined as CDAI score <150 points (*statistically significant versus placebo at $P < 0.05$). B, Rates of clinical response at weeks 6 and 12 (defined as a decrease in CDAI score ≥100 points compared with week 0; *statistically significant versus placebo at $P < 0.05$). C, Rates of clinical remission at week 6, stratified by baseline CRP levels (CRP ≥1 mg/dL or CRP <1 mg/dL). D, Rates of clinical remission at week 6, stratified by baseline history of anti-TNF treatment N.S., not statistically significant versus placebo at $P < 0.05$.

Treat to target: A concept dating back to 2010



Treat to target: A concept dating back to 2010



- Panacccione R, ECCO Prague 2010

Clinical Trial > Lancet. 2017 Dec 23;390(10114):2779-2789.
doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean-Frederic Colombel [1], Remo Panaccione [2], Peter Bossuyt [3], Milan Lukas [4], Filip Baert [5],



Clinical Trial > Gut. 2020 Apr;69(4):658-664. doi: 10.1136/gutjnl-2019-318256.
Epub 2019 Jul 8.

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Remo Panaccione [1], Jean-Frederic Colombel [2], Simon P L Travis [3], Peter Bossuyt [4],

Wait your turn

MY CUSTOM FILTERS

RESULTS BY YEAR



Wait your turn

Randomized Controlled Trial > Lancet. 2022 May 28;399(10340):2015-2030.
doi: 10.1016/S0140-6736(22)00467-6.

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D'Haens [1], Remo Panaccione [2], Filip Baert [3], Peter Bossuyt [4], Jean-Frederic Colombel [5],

Clinical Trial > Lancet. 2022 May 28;399(10340):2031-2046.
doi: 10.1016/S0140-6736(22)00466-4.

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante [1], Remo Panaccione [2], Filip Baert [3], Peter Bossuyt [4], Jean-Frederic Colombel [5],

Clinical Trial > Lancet. 2022 Jun 4;399(10341):2113-2128.
doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese [1], Séverine Vermeire [2], Wen Zhou [3], Aileen L Pangan [3], Jesse Siffledeen [4], Susan Greenbloom [5], Xavier Hébuterne [6], Geert D'Haens [7], Hiroshi Nakase [8], Julian Panés [9], Peter D R Higgins [10], Pascal Juillerat [11], James O Lindsay [12], Edward V Loftus Jr [13], William J Sandborn [14], Walter Reinisch [15], Min-Hu Chen [16], Yuri Sanchez Gonzalez [3], Bidan Huang [3], Wangang Xie [3], John Liu [3], Michael A Weinreich [3], Remo Panaccione [17]

> Aliment Pharmacol Ther. 2024 Feb;59(3):393-408. doi: 10.1111/apt.17816. Epub 2023 Nov 27.

Alimentary pharmacology & therapeutics

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis

Remo Panaccione [1], Silvio Danese [2], Wen Zhou [3], Justin Klaff [3], Dapo Ilo [3], Xuan Yao [3],

Wait your turn

Clinical Trial > Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146.
doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14.

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese [1], Remo Panaccione [2], Brian G Feagan [3], Anita Afzali [4], David T Rubin [5],

GALAXI 2/3 Composite endpoints v. placebo





Placebo | GUS 200 mg IV q4w → 100 mg SC q8w | GUS 200 mg IV q4w → 200 mg SC q4w

Clinical Response: ≥100-point reduction from baseline in CDAI or CDAI < 150
Clinical Remission: CDAI < 150
Endoscopic Response: ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2

Panaccione et al DDW 2024

Guselkumab vs Ustekinumab: Ranked secondary endpoints week 48



Endoscopic Response: ≥50% improvement from baseline in SES-CD or SES-CD ≤ 2
Endoscopic Remission: SES-CD ≤ 4 and a ≥2-point reduction from baseline and no subscore greater than 1 in any individual component
Clinical Remission: CDAI < 150
Deep Remission: Clinical Remission and Endoscopic Remission

Panaccione et al DDW 2024

Phase 3, Double-blind, Treat-through Design: GRAVITI

Key eligibility criteria

- Moderately to severely active CD (CDAI score 220–450 AND either mean daily SF count ≥4 OR AP score ≥2) and SES-CD score ≥6 (or ≥4 for isolated ileal disease)
- Inadequate response/intolerance to oral corticosteroids, 6-MP/AZA/MTX, or biologic therapies[a]



Randomization stratified by:

- CDAI score (≤300 or >300)
- SES-CD (≤12 or >12)
- Prior BIO-failure status

: Guselkumab 100 mg

: Guselkumab 200 mg

E : Endoscopy

U : Study unblinding

Rescue Treatment Criteria

- CDAI score > 220 and < 70-point reduction from baseline CDAI at both Weeks 12 and 16 **OR**
- SES-CD score increase by ≥ 50% from baseline at Week 12

Rescue Treatment for Guselkumab Arms: Sham matching placebo SC to maintain the blind

AP=abdominal pain. BIO=biologic. CDAI=Crohn's disease activity index. SC=subcutaneous. SES-CD=simple endoscopic score for Crohn's disease. SF=stool frequency.

[a] Biologic therapies: TNF antagonists or vedolizumab

Panaccione et al ACG 2024

GRAVITI: SC GUS Clinical Remission at Week 12



Clinical remission: CDAI score <150

BIO-IR= history of inadequate response or intolerance to previous biologic therapy.
Note: Clinical remission at Week 12 was **multiplicity-controlled** for the overall population, not the BIO-naïve and BIO-IR subpopulations.

Panaccione et al ACG 2024

GRAVITI: SC GUS Endoscopic Response at Week 12



Endoscopic response: ≥50% improvement from baseline in SES-CD score

BIO-IR= history of inadequate response or intolerance to previous biologic therapy.
Note: Endoscopic response at Week 12 was **multiplicity-controlled** for the overall population, not the BIO-naïve and BIO-IR subpopulations.

Panaccione et al ACG 2024

Risankizumab Platform Combination Study: Target -CD



University of Calgary: IBD unit evolution



2005
Establish The IBD Nurse Practitoner position (Joan Heatherington)

2007
Stephanie Wilson MD arrives in Calgary

2008
Recruit Subrata Ghosh;
Gil Kaplan returns

2008
IBD Fellowship established

2009
AHFMR Team grant

2010
Enhance IBD endoscopy
(Marietta Iaccuci)

2013
Establish IBD pregnancy clinic
(Cynthia Seow)

2013
POCUS becomes a reality
(Kerri Novak)

2014
Canadian National IBD Network established
(PACE)

$ $ $



$ $ $

University of Calgary: IBD unit evolution

2014
Expand Nurse Practitioner Program

2015
Expand Footprint to SHC

2019
Chris Ma Returns

2024
Joelle St. Pierrre returns

Research Leadership Award: Who really matters

Prof. Remo Panaccione

Prof. Gil Kaplan

Prof. Cynthia Seow

Prof. Paulo Kotze
Brazil

Assoc. Prof Kerri Novak

Assoc. Prof. Cathy Lu

Assoc. Prof Chris Ma

Assist. Prof. Joelle St. Pierre

Build partnerships



UNIVERSITY OF ALBERTA
FACULTY OF MEDICINE & DENTISTRY

FACULTY OF MEDICINE | UNIVERSITY OF CALGARY

Remember the little seed in the Styrofoam cup. The roots go down and the plant goes up and nobody really knows how or why, but we are all like that.

Robert Fulghum

quotefancy



THANK YOU

INFLAMMATORY
BOWEL DISEASE UNIT
UNIVERSITY OF CALGARY